Literature DB >> 9347375

Surgical management of Candida suppurative thrombophlebitis of superior vena cava after central venous catheterization.

E Garcia1, I Granier, A Geissler, M D Boespflug, P E Magnan, J Durand-Gasselin.   

Abstract

Septic deep venous thrombosis is a major complication associated with central venous catheterization in intensive care units. The most common causative organisms are Staphylococcus aureus, gram-negative bacilli and Candida species. The incidence of Candida infections is increasing, especially in intensive care patients receiving total parenteral nutrition and long-term broad-spectrum antibiotics. Although intravascular catheter-induced septic thrombophlebitis is quite common, superior vena cava obstruction is a rare complication. However, few data exist concerning the best strategy for managing septic thrombophlebitis, especially when medical therapy fails. We report successful surgical management of Candida albicans suppurative thrombosis of the superior vena cava in a young patient.

Entities:  

Mesh:

Year:  1997        PMID: 9347375     DOI: 10.1007/s001340050446

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  3 in total

1.  Failure of new antifungals to control Candida thrombophlebitis.

Authors:  Mathieu Gazon; Marc O Robert; Serge Duperret; Patricia Branche; Jean P Viale
Journal:  Intensive Care Med       Date:  2005-03-22       Impact factor: 17.440

2.  Echocardiography practice, training and accreditation in the intensive care: document for the World Interactive Network Focused on Critical Ultrasound (WINFOCUS).

Authors:  Susanna Price; Gabriele Via; Erik Sloth; Fabio Guarracino; Raoul Breitkreutz; Emanuele Catena; Daniel Talmor
Journal:  Cardiovasc Ultrasound       Date:  2008-10-06       Impact factor: 2.062

3.  Fatal peripheral candidal suppurative thrombophlebitis in a postoperative patient.

Authors:  Suk-Kyung Hong; So-Hyun Nam; Hee Cheol Kim
Journal:  J Korean Med Sci       Date:  2008-12-24       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.